logo
  

Dechra Pharma To Buy Worldwide Rights To Verdinexor For Dogs

Dechra Pharmaceuticals PLC (DPH.L) announced Tuesday that it has agreed terms with Anivive Lifesciences, Inc. to acquire the worldwide rights to verdinexor, a novel treatment of all forms and stages of canine lymphoma in dogs.

Under the deal terms, Dechra will buy the global product rights and a first right of refusal for other species along with the trademark -Laverdia.

Dechra said it will acquire the worldwide marketing rights, the rights to the intellectual property, the marketing authorisations (when granted) and associated regulatory documentation, supply contracts with third parties in relation to the raw material and manufacture of the finished product. No other assets are being transferred to Dechra.

The product, currently sold as LAVERDIA-CA1 in the USA is a novel oral selective inhibitor of nuclear export or SINE drug and the first oral tablet for canine lymphoma.

The drug was conditionally approved by the FDA Center for Veterinary Medicine on January 11, 2021.

Sales of the product in the USA commenced under the conditional approval in July 2021. Full dossier submissions are planned for USA, UK, EU, Brazil, Australia, Japan and Canada.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ryanair Holdings Plc reported Monday a loss in its fiscal year 2022, narrower than last year, with strong growth in traffic and load factor. Looking ahead, the company said it expects to return to reasonable profitability in fiscal 2023. Shares of the low fares airline were losing around 4 percent in the morning trading in Germany. The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert against Weis Markets' ready-to-eat or RTE General Tso Chicken meals due to misbranding and undeclared milk, a known allergen. The RTE General Tso Chicken meals were prepared, labeled and sold in the Deli area at Weis Markets stores between April 13 and May 11, 2022. Deutsche Telekom AG on Friday raised its fiscal 2022 adjusted earnings forecast after reporting significantly higher net profit in its first quarter. Shares of the German telecom major were gaining around 1 percent in the morning trading in Germany. For fiscal 2022, the company now expects to post adjusted EBITDA AL of more than 36.6 billion euros.
RELATED NEWS
Follow RTT